PubRank

Edward A Fisher

Author PubWeight™ 228.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010 6.93
3 The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003 6.34
4 Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011 4.34
5 Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011 4.21
6 Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 2004 3.85
7 Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013 3.85
8 Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007 3.40
9 miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011 3.35
10 Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005 3.15
11 Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013 3.07
12 Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 2006 3.00
13 Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007 2.99
14 Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008 2.98
15 The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol 2012 2.69
16 Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell 2006 2.54
17 Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 2010 2.43
18 Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007 2.34
19 Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004 2.27
20 Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A 2003 2.23
21 Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013 2.20
22 HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A 2011 2.16
23 Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2002 2.13
24 Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008 1.98
25 Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 2009 1.89
26 Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002 1.87
27 MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006 1.79
28 Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011 1.79
29 MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol 2002 1.79
30 Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc Biol 2008 1.79
31 Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004 1.77
32 Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 2012 1.71
33 Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 2003 1.68
34 Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004 1.67
35 LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010 1.67
36 Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2014 1.66
37 Mouse model of heterotopic aortic arch transplantation. J Surg Res 2003 1.66
38 Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 2009 1.65
39 Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol 2013 1.64
40 Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation. Arterioscler Thromb Vasc Biol 2004 1.62
41 Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging 2007 1.52
42 The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res 2008 1.48
43 Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res 2013 1.47
44 Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging 2011 1.46
45 Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc Natl Acad Sci U S A 2008 1.45
46 Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006 1.42
47 Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem 2003 1.37
48 Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem 2003 1.36
49 Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 2011 1.35
50 An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008 1.34
51 Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003 1.31
52 High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004 1.30
53 High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 2009 1.30
54 Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm 2010 1.28
55 The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab 2008 1.27
56 Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol 2004 1.27
57 Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 2005 1.27
58 Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One 2011 1.25
59 Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem 2007 1.24
60 Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008 1.24
61 The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 2013 1.22
62 Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011 1.22
63 Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013 1.21
64 RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 2010 1.21
65 Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002 1.21
66 The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 2011 1.21
67 Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol 2012 1.15
68 Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res 2010 1.11
69 Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? Curr Opin Clin Nutr Metab Care 2005 1.10
70 Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One 2012 1.09
71 The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic reticulum-associated degradation (ERAD). J Biol Chem 2007 1.07
72 Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2002 1.07
73 Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008 1.07
74 Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 2013 1.07
75 Connexin40 imparts conduction heterogeneity to atrial tissue. Circ Res 2008 1.06
76 Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem 2009 1.05
77 Laser capture microdissection for analysis of macrophage gene expression from atherosclerotic lesions. Methods Mol Biol 2005 1.05
78 Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis 2013 1.05
79 Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques: mechanism for macrophage retention and survival. Arterioscler Thromb Vasc Biol 2013 1.05
80 High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 2014 1.04
81 The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis. J Biol Chem 2001 1.03
82 MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest 2015 1.03
83 Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc Imaging 2012 1.00
84 Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol 2007 1.00
85 HDL induces the expression of the M2 macrophage markers arginase 1 and Fizz-1 in a STAT6-dependent process. PLoS One 2013 0.99
86 Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol Cell Biol 2008 0.99
87 Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am J Hum Genet 2012 0.99
88 Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem 2014 0.98
89 Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett 2010 0.98
90 Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler Thromb Vasc Biol 2013 0.97
91 High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein. Proc Natl Acad Sci U S A 2013 0.96
92 Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation 2013 0.96
93 LXRα regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res 2011 0.96
94 The endosomal protein-sorting receptor sortilin has a role in trafficking α-1 antitrypsin. Genetics 2012 0.95
95 Vesicular trafficking of hepatic apolipoprotein B100 and its maturation to very low-density lipoprotein particles; studies from cells and cell-free systems. Trends Cardiovasc Med 2004 0.94
96 Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat Clin Pract Cardiovasc Med 2004 0.93
97 Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002 0.93
98 Non-invasive MRI of mouse models of atherosclerosis. NMR Biomed 2007 0.92
99 Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res 2011 0.92
100 Myristic acid increases dense lipoprotein secretion by inhibiting apoB degradation and triglyceride recruitment. J Lipid Res 2002 0.92
101 Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2002 0.92
102 HDL as a contrast agent for medical imaging. Clin Lipidol 2009 0.92
103 TLR signaling and trapped vascular dendritic cells in the development of atherosclerosis. Trends Immunol 2006 0.91
104 Insulin-stimulated degradation of apolipoprotein B100: roles of class II phosphatidylinositol-3-kinase and autophagy. PLoS One 2013 0.91
105 High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J Phys Chem B 2009 0.91
106 Protein disulfide isomerases contribute differentially to the endoplasmic reticulum-associated degradation of apolipoprotein B and other substrates. Mol Biol Cell 2011 0.90
107 Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging 2013 0.90
108 Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem 2007 0.90
109 Subphysiologic apolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004 0.90
110 Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention? J Innate Immun 2012 0.90
111 HDL and cardiovascular risk: time to call the plumber? Circ Res 2012 0.90
112 A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. J Leukoc Biol 2010 0.89
113 Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation. J Lipid Res 2012 0.89
114 Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells. FASEB J 2011 0.87
115 Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin Drug Discov 2012 0.87
116 Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J Vasc Res 2004 0.86
117 Serial, noninvasive, in vivo magnetic resonance microscopy detects the development of atherosclerosis in apolipoprotein E-deficient mice and its progression by arterial wall remodeling. J Magn Reson Imaging 2003 0.86
118 ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 2012 0.86
119 Laser capture microdissection for analysis of macrophage gene expression from atherosclerotic lesions. Methods Mol Biol 2013 0.85
120 Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis 2013 0.85
121 A real time chemotaxis assay unveils unique migratory profiles amongst different primary murine macrophages. PLoS One 2013 0.84
122 South Asians and risk of cardiovascular disease: current insights and trends. Ethn Dis 2010 0.84
123 Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv Healthc Mater 2014 0.84
124 Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet domains, not pause transfer sequences. J Biol Chem 2006 0.84
125 Hypoxia in murine atherosclerotic plaques and its adverse effects on macrophages. Trends Cardiovasc Med 2013 0.83
126 Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Circ Res 2017 0.83
127 The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100. Biochemistry 2002 0.82
128 Short-term pacing in the mouse alters cardiac expression of connexin43. BMC Physiol 2008 0.82
129 The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Investig Drugs 2009 0.82
130 Globular warming: how fat gets to the furnace. Nat Med 2011 0.82
131 Particulate air pollution and carotid artery stenosis. J Am Coll Cardiol 2015 0.81
132 Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun 2005 0.81
133 Rat carboxylesterase ES-4 enzyme functions as a major hepatic neutral cholesteryl ester hydrolase. J Biol Chem 2011 0.80
134 The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques. Bioconjug Chem 2013 0.80
135 The presence, characterization and prognosis of coronary plaques among patients with zero coronary calcium scores. Int J Cardiovasc Imaging 2010 0.80
136 Dysfunctional HDL takes its toll in chronic kidney disease. Immunity 2013 0.80
137 A regulator of secretory vesicle size, Kelch-like protein 12, facilitates the secretion of apolipoprotein B100 and very-low-density lipoproteins--brief report. Arterioscler Thromb Vasc Biol 2013 0.79
138 The double-edged sword of fibronectin in atherosclerosis. EMBO Mol Med 2012 0.79
139 Decreased connexin43 expression in the mouse heart potentiates pacing-induced remodeling of repolarizing currents. Am J Physiol Heart Circ Physiol 2008 0.79
140 Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. Atherosclerosis 2002 0.79
141 Docosahexaenoic acid impairs the maturation of very low density lipoproteins in rat hepatic cells. J Lipid Res 2013 0.78
142 Macrophages, atherosclerosis and the potential of netrin-1 as a novel target for future therapeutic intervention. Future Cardiol 2012 0.78
143 Plasma carboxyl ester lipase activity modulates apolipoprotein B-containing lipoprotein metabolism in a transgenic mouse model. Metabolism 2008 0.78
144 Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases. Curr Cardiovasc Imaging Rep 2013 0.77
145 Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 2009 0.77
146 Therapeutic approach to childhood hypercholesterolemia. Pediatr Endocrinol Rev 2007 0.76
147 Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin Cardiol 2006 0.76
148 Exercise-induced increases in oxidized low-density lipoprotein are associated with adverse outcomes in chronic heart failure. J Card Fail 2007 0.76
149 Quantification of the plasma clearance kinetics of a gadolinium-based contrast agent by photoinduced triplet harvesting. Anal Chem 2012 0.75
150 Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol 2017 0.75
151 Cholesterol 27-hydroxylase but not apolipoprotein apoE contributes to A2A adenosine receptor stimulated reverse cholesterol transport. Inflammation 2012 0.75
152 Introduction for National Cholesterol Month. Arterioscler Thromb Vasc Biol 2011 0.75
153 Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2017 0.75
154 A rare case of a coronary vascular ring arising from an anomalous single coronary artery. J Invasive Cardiol 2012 0.75
155 Focus on obesity. Arterioscler Thromb Vasc Biol 2010 0.75
156 Physiological correlates of densely calcified coronary lesions on coronary computed tomography angiography among patients with low-to-intermediate coronary artery disease likelihood. Coron Artery Dis 2011 0.75
157 Summing up. Arterioscler Thromb Vasc Biol 2012 0.75
158 The editor in chief position in transition. Arterioscler Thromb Vasc Biol 2011 0.75